Entrada Therapeutics (TRDA) EBIT (2020 - 2026)

Entrada Therapeutics has reported EBIT for 7 years, with the latest figure at -$42.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 94.14% year-over-year to -$42.3 million; the trailing twelve-month figure through Mar 2026 stood at -$178.4 million (down 4443.01% YoY), and the FY2025 full-year result was -$157.9 million, down 435.87% from the prior year.
• EBIT for Q1 2026 stood at -$42.3 million, roughly flat from -$42.2 million in the prior quarter.
• The five-year high for EBIT was $53.4 million in Q2 2024, with the low at -$47.1 million in Q3 2025.
• Average EBIT over 5 years is -$14.9 million, with a median of -$21.8 million recorded in 2025.
• Year-over-year, EBIT jumped 465.28% in 2024 and sank 619.41% in 2025.
• Tracing TRDA's EBIT over 5 years: stood at -$25.6 million in 2022, then soared by 119.18% to $4.9 million in 2023, then tumbled by 219.61% to -$5.9 million in 2024, then slumped by 619.41% to -$42.2 million in 2025, then retreated by 0.23% to -$42.3 million in 2026.
• The last three EBIT figures came in at -$42.3 million (Q1 2026), -$42.2 million (Q4 2025), and -$47.1 million (Q3 2025), per Business Quant data.

Peer Comparison